BHC icon

Bausch Health

7.44 USD
+0.18
2.48%
Updated Feb 5, 12:54 PM EST
1 day
2.48%
5 days
-0.80%
1 month
-4.62%
3 months
-23.22%
6 months
42.26%
Year to date
-6.30%
1 year
-4.25%
5 years
-74.40%
10 years
-95.39%
 

About: Bausch Health Companies Inc is a global specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum revenue from the Bausch + Lomb segment.

Employees: 20,270

0
Funds holding %
of 6,831 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

14% more funds holding in top 10

Funds holding in top 10: 7 [Q2] → 8 (+1) [Q3]

6% more capital invested

Capital invested by funds: $1.96B [Q2] → $2.08B (+$115M) [Q3]

7.37% less ownership

Funds ownership: 76.65% [Q2] → 69.28% (-7.37%) [Q3]

10% less funds holding

Funds holding: 231 [Q2] → 208 (-23) [Q3]

34% less repeat investments, than reductions

Existing positions increased: 45 | Existing positions reduced: 68

44% less first-time investments, than exits

New positions opened: 27 | Existing positions closed: 48

71% less call options, than puts

Call options by funds: $41.8M | Put options by funds: $146M

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$10
34%
upside
Avg. target
$10
34%
upside
High target
$10
34%
upside

1 analyst rating

positive
0%
neutral
100%
negative
0%
RBC Capital
Douglas Miehm
71% 1-year accuracy
15 / 21 met price target
34%upside
$10
Sector Perform
Maintained
30 Jan 2025

Financial journalist opinion

Based on 16 articles about BHC published over the past 30 days

Neutral
Accesswire
1 week ago
Bausch Health to Announce Fourth Quarter and Full Year 2024 Results on February 19, 2025
Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release fourth quarter and full year 2024 financial results after market close on Wednesday, February 19, 2025. Bausch Health will host a conference call and live webcast at 5:00 p.m.
Bausch Health to Announce Fourth Quarter and Full Year 2024 Results on February 19, 2025
Neutral
Accesswire
1 week ago
Bausch Health to Announce Fourth Quarter and Full Year 2024 Results on February 19, 2025
LAVAL, QC / ACCESS Newswire / January 23, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release fourth quarter and full year 2024 financial results after market close on Wednesday, February 19, 2025. Bausch Health will host a conference call and live webcast at 5:00 p.m.
Bausch Health to Announce Fourth Quarter and Full Year 2024 Results on February 19, 2025
Neutral
Business Wire
2 weeks ago
Bausch + Lomb Will Release Fourth-Quarter and Full-Year 2024 Financial Results on February 19
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its fourth-quarter and full-year 2024 financial results on Wednesday, February 19, 2025. Bausch + Lomb will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website p.
Bausch + Lomb Will Release Fourth-Quarter and Full-Year 2024 Financial Results on February 19
Neutral
Accesswire
2 weeks ago
Bausch Health Statement on Selection of XIFAXAN(R) (rifaximin) for Inflation Reduction Act's Medicare Negotiation Program
LAVAL, QC / ACCESS Newswire / January 17, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals, today acknowledged that the Centers for Medicare and Medicaid Services (CMS) has selected XIFAXAN® (rifaximin) 550 mg tablets as one of the medicines for the second round of negotiation as part of the Inflation Reduction Act with an initial price applicability in 2027 of the Drug Price Negotiation program. We look forward to engaging in open and transparent conversations with CMS, where we will share information on the value that XIFAXAN® delivers for the healthcare system in addition to sharing recommendations from The American Association for the Study of Liver Diseases (AASLD) and the European Association for the Study of the Liver (EASL) who gave XIFAXAN® the highest possible recommendation (Grade I, A,1) via their practice guidelines.
Bausch Health Statement on Selection of XIFAXAN(R) (rifaximin) for Inflation Reduction Act's Medicare Negotiation Program
Positive
Zacks Investment Research
2 weeks ago
Wall Street Analysts See a 25.5% Upside in Bausch (BHC): Can the Stock Really Move This High?
The mean of analysts' price targets for Bausch (BHC) points to a 25.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Wall Street Analysts See a 25.5% Upside in Bausch (BHC): Can the Stock Really Move This High?
Negative
CNBC Television
3 weeks ago
Bausch + Lomb CEO on the negative impact of screen time on eye health
Brent Saunders, Bausch and Lomb CEO, discusses how too much screen time can have a negative impact on vision.
Bausch + Lomb CEO on the negative impact of screen time on eye health
Positive
CNBC Television
3 weeks ago
Bausch and Lomb CEO: Right on track with our important initiatives
Brent Saunders, Bausch and Lomb CEO, joins 'Money Movers' to discuss how Saunders has changed the portfolio in his time as chief executive, what the growth is like for Bausch and Lomb, and much more.
Bausch and Lomb CEO: Right on track with our important initiatives
Neutral
Business Wire
3 weeks ago
Bausch + Lomb Bolsters Pipeline with Acquisition of Whitecap Biosciences
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced an affiliate has acquired Whitecap Biosciences, LLC, which is currently developing two innovative therapies for potential use in glaucoma and geographic atrophy (GA). The acquisition strengthens Bausch + Lomb's expanding clinical-stage pipeline. “We're focused on finding treatments that address unmet needs or si.
Bausch + Lomb Bolsters Pipeline with Acquisition of Whitecap Biosciences
Neutral
GlobeNewsWire
3 weeks ago
George Medicines signs exclusive licensing agreement with Bausch Health to commercialize GMRx2 in Canada, Mexico, Columbia and Central America
George Medicines signs exclusive licensing agreement with Bausch Health to commercialize GMRx2 in Canada, Mexico, Columbia and Central America
George Medicines signs exclusive licensing agreement with Bausch Health to commercialize GMRx2 in Canada, Mexico, Columbia and Central America
Neutral
Business Wire
3 weeks ago
Bausch + Lomb Launches enVista Aspire™ Intermediate Optimized Monofocal and Toric Intraocular Lenses in the European Union
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the commercial launch of the enVista Aspire monofocal and toric intraocular lenses (IOLs) in the European Union after receiving a CE Mark late last year. enVista Aspire combines novel Intermediate Optimized optics, which are designed for a broader depth of focus*, with the proven benefits of the enVista® platfor.
Bausch + Lomb Launches enVista Aspire™ Intermediate Optimized Monofocal and Toric Intraocular Lenses in the European Union
Charts implemented using Lightweight Charts™